The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
An integrated assay using proprietary RNAscope™ and miRNAscope™ technologies to measure the biodistribution and function of novel gene therapies and endogenous regulatory RNAs. Small regulatory RNAs, ...
MINNEAPOLIS and SEATTLE, Aug. 6, 2020 /PRNewswire/ -- Bio-Techne (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
In this webinar we will provide an overview of RNAscope™ ISH technology, then discuss our new RNAscope multiomic applications coming soon. RNAscope is the gold standard for RNA ISH -providing ...
The RNAscope in situ hybridization (ISH) technology is a powerful method for detecting gene expression with spatial and morphological tissue context. In this webinar, we will focus on an Integrated Co ...
MINNEAPOLIS, July 27, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD), a Bio-Techne brand, RNAscope in situ ...
Advanced Cell Diagnostics, Inc. (ACD) today announced the results of its clinical study utilizing RNAscope™ technology to detect human papillomavirus (HPV) E6/E7 mRNA in routine clinical specimens of ...
Advanced Cell Diagnostics Inc. (ACD), the market leader in tissue-based RNA analysis tools for molecular pathology, has announced the release of its next version RNAscope ® in situ hybridization (ISH) ...
(RTTNews) - Bio-Techne Corp. (TECH) said that its RNAscope technology aids in the retrospective tissue diagnosis of covid-19 in cases with no previous testing for SARS-CoV-2. The company said it is ...
Advanced Cell Diagnostics, Inc. has announced that Merrimack Pharmaceuticals, Inc. is using ACD's RNAscope technology to select patients for its Phase 2 clinical trial of its product candidate MM-121.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results